Ozempic works by acting like the gut hormone GLP-1, which signals to the brain that a person has eaten, reducing appetite
Health Canada approval is expected for retatrutide in late 2026 or early 2027
These lawsuits allege that the drug has caused serious side effects such as pancreatic inflammation, thyroid cancer, kidney failure, and gastrointestinal issues, including stomach paralysis, which Novo Nordisk failed to warn patients about
This approach ensures that GLP-1 therapy is tailored to those most likely to benefit from improved metabolic health, weight reduction, and reduced risk of other health conditions such as cardiovascular issues and blood sugar imbalances
By the time patients are 1 year from their initial prescription, only 10% remain persistent
Some estimates suggest up to 25% of adults have some level of needle anxiety, which makes a daily drop or a patch sound like an easier alternative